b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">30633446</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>02</Month>\n            <Day>26</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1097-0347</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>41</Volume>\n                    <Issue>6</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>06</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Head &amp; neck</Title>\n                <ISOAbbreviation>Head Neck</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Paraganglioma of the head and neck region, treated with radiation therapy, a Rare Cancer Network study.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1770-1776</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.25611</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND">Paraganglioma of the head and neck (HNPGL) are rare often benign tumors. Surgery and radiation therapy (RT) are the main treatment choices. We present an analysis of outcome and toxicity after RT from 13 institutions of the Rare Cancer Network.</AbstractText>\n                <AbstractText Label="METHODS">Data were collected using a questionnaire concerning patients\' characteristics, treatment, and outcome. A total of 81 patients with 82 HNPGL were analyzed.</AbstractText>\n                <AbstractText Label="RESULTS">The median follow-up was 48\xe2\x80\x89months (1-456). Sixty-two lesions were treated with conventional RT and 20 lesions with stereotactic RT. Local control (LC) was achieved in 69 out of 77 lesions. Late toxicity occurred in 17 patients. Patients treated with stereotactic RT experienced neither disease progression nor late toxicity. Four patients with a follow-up longer than 20\xe2\x80\x89years experienced disease progression.</AbstractText>\n                <AbstractText Label="CONCLUSION">RT for HNPGL offered good local control with acceptable toxicity. Stereotactic RT might offer better results. Long-term follow-up is required.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 2019 Wiley Periodicals, Inc.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Lassen-Ramshad</LastName>\n                    <ForeName>Yasmin</ForeName>\n                    <Initials>Y</Initials>\n                    <Identifier Source="ORCID">0000-0002-4992-3231</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ozyar</LastName>\n                    <ForeName>Enis</ForeName>\n                    <Initials>E</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Acibadem M.A. Aydinlar University, School of Medicine, Department of Radiation Oncology, Turkey.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Alanyali</LastName>\n                    <ForeName>Senem</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, Ege University Faculty of Medicine, Turkey.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Poortmans</LastName>\n                    <ForeName>Philip</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, Institut Curie, Paris, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>van Houtte</LastName>\n                    <ForeName>Paul</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, Jules Bordet Institute, Brussels, Belgium.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Sohawon</LastName>\n                    <ForeName>Schoeb</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, Jules Bordet Institute, Brussels, Belgium.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Esassolak</LastName>\n                    <ForeName>Mustafa</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, Ege University Faculty of Medicine, Turkey.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Krengli</LastName>\n                    <ForeName>Marco</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiotherapy, University of Piemonte Orientale Novara, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Villa</LastName>\n                    <ForeName>Salvador</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, Catalan Institute of Oncoloy, Badalona, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Miller</LastName>\n                    <ForeName>Robert</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Demiroz</LastName>\n                    <ForeName>Candan</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Uludag University Faculty of Medicine, Radiation Oncology Clinical Division, Turkey.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Akyurek</LastName>\n                    <ForeName>Serap</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiotherapy, Ankara University School of Medicine, Turkey.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Aggerholm-Pedersen</LastName>\n                    <ForeName>Ninna</ForeName>\n                    <Initials>N</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Thariat</LastName>\n                    <ForeName>Juliette</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Radiation Oncology Department, Centre Francois Baclesse, Caen, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>01</Month>\n                <Day>11</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Head Neck</MedlineTA>\n            <NlmUniqueID>8902541</NlmUniqueID>\n            <ISSNLinking>1043-3074</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <CommentsCorrectionsList>\n            <CommentsCorrections RefType="CommentIn">\n                <RefSource>Head Neck. 2019 Aug;41(8):2835-2836</RefSource>\n                <PMID Version="1">31034657</PMID>\n            </CommentsCorrections>\n            <CommentsCorrections RefType="CommentIn">\n                <RefSource>Head Neck. 2019 Aug;41(8):2837-2838</RefSource>\n                <PMID Version="1">31058391</PMID>\n            </CommentsCorrections>\n        </CommentsCorrectionsList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>07</Month>\n                <Day>02</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2018</Year>\n                <Month>10</Month>\n                <Day>29</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2018</Year>\n                <Month>12</Month>\n                <Day>10</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>1</Month>\n                <Day>12</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>1</Month>\n                <Day>12</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>1</Month>\n                <Day>12</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30633446</ArticleId>\n            <ArticleId IdType="doi">10.1002/hed.25611</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'